Nature.com: HPBCD treatment improves learning and executive function in Alzheimer model mice
Earlier we have reported on a patent appication related to HPBCD treatment in Alzheimer’s disease based on the invention of
Tag: Alzheimer’s disease
MIT scientists filed patent for HPBCD treatment in Alzheimer’s disease
Li-Huei Tsai, director of Picower Institute for Learning and Memory (Massachusetts Institute of Technology) and her coworkers recently filed a patent
Cyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through
Cyclo Therapeutics Submits IND Application to U.S. FDA to Advance Trappsol® Cyclo™ in Phase 2 Study for Treatment of Alzheimer’s Disease
Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
Cyclo Therapeutics Announces Pricing of $12.5 Million Public Offering
Transaction Includes Uplisting to Nasdaq and Reverse Stock Split Cyclo Therapeutics, Inc., a clinical stage biotechnology company developing a cyclodextrin
Cyclo Therapeutics Reports on Eighteen Month Expanded Access Program in Single Alzheimer’s Patient
Cyclo Therapeutics, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C
International Conference on Alzheimer’s Disease & Dementia
International Conference on Alzheimer’s Disease & Dementia is scheduled Hilton Rome Airport ,Rome, Italy from July 20 – 22, 2020. This International Conference
Underdog Launches With $4M to Target “Toxic” Form of Cholesterol
Underdog Pharmaceuticals has launched with nearly $4 million in seed funding to develop treatments for atherosclerosis, a progressive condition in